CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

Contents

List of contributors *page* xv
Preface xvii
Foreword xix
List of abbreviations xxi

1 Pathophysiology of the alloimmune cytopenias 1
Andrew G Hadley and Craig Turner

1.1 Maternal alloimmunization 1
1.1.1 Some key events in the humoral immune response 1
1.1.2 The maternal alloimmune response to fetal red cells 4
1.1.3 The maternal alloimmune response to fetal platelets 5
1.1.4 The maternal alloimmune response to fetal neutrophils 6
1.2 Transfer of IgG to the fetus 6
1.3 The immune destruction of blood cells in the fetus 7
1.3.1 IgG and Fcγ receptors 8
1.3.2 The immune destruction of fetal red cells 8
1.3.3 The immune destruction of fetal platelets 12
1.3.4 The immune destruction of fetal neutrophils 14
1.4 Conclusions 14
1.5 References 14

2 Blood group antibodies in haemolytic disease of the fetus and newborn 21
Geoff Daniels

2.1 Introduction 21
2.2 Blood group terminology 21
2.3 The genetics of blood groups 24
2.4 The effect of antigen expression on the pathogenicity and severity of HDFN 25
2.5 Antibodies that most commonly cause moderate or severe HDFN 27

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

2.5.1 Anti-D 27
2.5.2 Other antibodies to Rh-system antigens 30
2.5.3 Anti-K 31
2.5.4 Other antibodies to Kell-system antigens 32
2.6 Antibodies that most commonly cause mild HDFN 33
2.6.1 The ABO system 33
2.7 Antibodies that rarely cause HDFN 34
2.7.1 MNS system 34
2.7.2 Duffy system 35
2.7.3 Kidd system 35
2.7.4 Diego system 35
2.7.5 Colton system 36
2.7.6 Other antigens 36
2.8 Antibodies that do not cause HDFN 36
2.9 Conclusions 37
2.10 References 37

3 Basis and practice of screening for haemolytic disease of the fetus and newborn 41
Geoff Poole

3.1 Introduction 41
3.2 The basis of screening for HDFN 41
3.3 Antenatal screening tests performed in the blood transfusion laboratory 42
3.3.1 Antiglobulin methods 42
3.3.2 Enzyme methods 46
3.3.3 The choice of red cells for screening tests 47
3.3.4 Manual versus automated methods 48
3.3.5 Timing of screening tests 49
3.4 The identification of red cell alloantibodies 50
3.4.1 Methods 50
3.4.2 The principles of antibody identification 51
3.4.3 Difficulties encountered in antibody identification 54
3.4.4 Implications of detecting a red cell alloantibody during pregnancy 55
3.5 Paternal and fetal phenotyping 56
3.5.1 Paternal phenotype 56
3.5.2 Fetal phenotype 57
3.6 Laboratory tests immediately following delivery 58
3.7 References 58

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

4 Epidemiology and screening for alloimmune thrombocytopenia 61
Lorna M Williamson and Michael F Murphy

4.1 Background 61
4.2 Epidemiology and the natural history of alloimmune thrombocytopenia 62
4.2.1 The incidence of maternal alloimmunization 62
4.2.2 The incidence of fetal thrombocytopenia due to maternal alloimmunization 62
4.2.3 The incidence of intracranial haemorrhage and other sequelae 63
4.2.4 The influence of obstetric history on clinical outcome 63
4.3 Criteria for antenatal screening for alloimmune thrombocytopenia 64
4.3.1 The condition should be an important health problem 64
4.3.2 The epidemiology of the condition should be known 65
4.3.3 The natural history of the condition should be understood 65
4.3.4 There should be a recognized latent period or early asymptomatic stage 65
4.3.5 All the cost-effective primary prevention interventions should have been implemented as far as practicable 66
4.3.6 There should be a simple, safe, precise and validated screening test 66
4.3.7 The distribution of test values in the target population should be known and a suitable cut-off level defined and agreed 66
4.3.8 The test should be acceptable to the population 67
4.3.9 There should be an agreed policy on the further diagnostic investigation of individuals with a positive result and on the choices available to those individuals 67
4.3.10 There should be an effective treatment or intervention for patients identified through early detection 67
4.3.11 There should be agreed evidence-based policies covering which individuals should be offered treatment and the appropriate treatment to be offered 69
4.3.12 Clinical management of the condition and patient outcomes should be optimized by all health providers prior to participation in a screening programme 69
4.4 The cost-effectiveness of a screening programme 69
4.5 Conclusions 70
4.6 References 70

5 Principles of antibody-mediated immune suppression and the prevention of maternal RhD alloimmunization 73
Belinda Kumpel

5.1 Haemolytic disease of the fetus and newborn due to anti-D 73
5.2 Experimental studies on the prevention of RhD immunization 74

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

5.3 Clinical studies on the efficacy of RhD prophylaxis 75
5.3.1 Dose of anti-D 76
5.3.2 The current situation 77
5.4 Characteristics and requirements of RhD prophylaxis 78
5.4.1 Ratio of antibody to antigen required for suppression 78
5.4.2 Relationship of red cell clearance to antibody-mediated immune suppression 78
5.4.3 Protection afforded by ABO antibodies 79
5.4.4 Role of the spleen in RhD prophylaxis 79
5.4.5 Timing of passive anti-D 79
5.4.6 Time of detection of anti-D response 79
5.4.7 Effect of passive anti-D on subsequent immunization 80
5.4.8 Effect of passive anti-D on an established primary response 80
5.4.9 Role of anti-D Fc fragments 80
5.4.10 Epitope specificity 80
5.5 Theories of the mechanism of action of prophylactic anti-D 81
5.5.1 Inhibition of B cells by crosslinking heterologous receptors 81
5.5.2 Anti-idiotypic antibodies 83
5.5.3 Masking of antigen sites 84
5.5.4 Clearance and destruction of D-positive red cells 84
5.6 Development of monoclonal anti-D for RhD prophylaxis 84
5.6.1 Production of monoclonal anti-D 85
5.6.2 Half-lives of monoclonal anti-D 85
5.6.3 In vitro functional activity of monoclonal anti-D 86
5.6.4 In vivo red cell clearance mediated by monoclonal anti-D 86
5.6.5 Suppression of the anti-D response by monoclonal anti-D 88
5.7 References 88

6 The clinical application of anti-D prophylaxis 97
Stan Urbaniak

6.1 Epidemiology 97
6.1.1 Causes and incidence of alloimmunization 97
6.1.2 Ethnic groups 97
6.1.3 Use of D-negative transfusions for young women 97
6.1.4 Relative importance of anti-D before and after the introduction of anti-D prophylaxis programmes 98
6.2 Prophylaxis programmes 98
6.2.1 Suppression of the immune response 98
6.2.2 Recommendations and guidelines 99
6.2.3 Effectiveness in Caucasian populations 101

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

6.2.4 Reasons for continued failures 101
6.2.5 Anti-D immunization during pregnancy 102
6.2.6 Antenatal administration of anti-D immunoglobulin 102
6.2.7 Anti-D immunoglobulin use on women with weak D or partial D 104
6.2.8 Anti-D immunoglobulin use after the accidental transfusion of D-positive red cells 104
6.3 Detection of fetal red cells in the maternal circulation 105
6.3.1 The Kleihauer–Betke acid-elution test 106
6.3.2 Flow cytometry 106
6.3.3 Serological tests of fetomaternal haemorrhage 107
6.3.4 Calculating the size of fetomaternal haemorrhage 107
6.4 Fetomaternal haemorrhage and dose of anti-D immunoglobulin 108
6.4.1 Fetomaternal haemorrhage at delivery 108
6.4.2 Bleeding during pregnancy 108
6.4.3 Spontaneous fetomaternal haemorrhage during first, second and third trimesters 109
6.4.4 Other significant events during pregnancy 110
6.4.5 Fetomaternal haemorrhage due to medical procedures 110
6.4.6 Calculation of the required dose of anti-D 111
6.5 Procurement of hyperimmune anti-D 112
6.5.1 Identification, recruitment, boosting and accreditation of donors 112
6.5.2 Manufacture of anti-D immunoglobulin and safety considerations 113
6.6 Economics of prophylaxis programmes 114
6.6.1 Cost-effectiveness of antenatal versus postnatal prophylaxis 114
6.7 Future developments 115
6.8 References 116

7 Fetal genotyping 121
Neil D Avent

7.1 Introduction 121
7.2 The polymerase chain reaction 121
7.2.1 Principle of the polymerase chain reaction 121
7.2.2 Polymerase chain reaction – restriction fragment length polymorphism analysis 122
7.2.3 Allele-specific primer amplification 122
7.3 PCR-based typing for clinically significant blood groups 124
7.3.1 The Rh system 125
7.3.2 Kell system 130
7.3.3 Duffy system 131
7.3.4 Kidd system 132
7.3.5 ABO system 132

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

7.4 Noninvasive testing 133
7.4.1 Detection of fetal RHD targets in genomic DNA extracted from fetal leukocytes in maternal blood 133
7.4.2 The detection of fetal RhD cDNA derived from RNA extracted from maternal blood 133
7.4.3 Detection of fetal RHD targets in genomic DNA extracted from maternal plasma 134
7.5 Future perspectives 134
7.6 References 135

8 Laboratory assays to determine the severity of haemolytic disease of the fetus and newborn 141
Andrew G Hadley

8.1 Introduction 141
8.2 Serological assays 141
8.3 Quantitative assays 144
8.4 Cellular assays 144
8.4.1 The K lymphocyte-mediated ADCC assay 145
8.4.2 The monocyte-mediated ADCC assay 146
8.4.3 The monocyte monolayer assay 146
8.4.4 The chemiluminescence test 147
8.5 A strategy for antenatal testing 148
8.6 References 149

9 Assessing the severity of haemolytic disease of the fetus and newborn: clinical aspects 153
Sherif Abdel-Fattah and Peter Soothill

9.1 Introduction 153
9.2 Noninvasive assessment 153
9.2.1 Previous obstetric history 153
9.2.2 Antibody levels 154
9.2.3 Ultrasound findings 156
9.2.4 Fetal heart rate monitoring 158
9.2.5 Fetal Doppler ultrasonography 159
9.3 Invasive testing 163
9.3.1 Amniocentesis 163
9.3.2 Fetal blood sampling 165
9.4 Conclusions 167
9.5 References 167

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

10 Antenatal therapy for haemolytic disease of the fetus and newborn 173
Kenneth J Moise Jr and Paul W Whitecar

10.1 Introduction 173
10.2 Plasmapheresis and intravenous immune globulin 173
10.2.1 Plasmapheresis 173
10.2.2 Intravenous immunoglobulin 175
10.3 Intrauterine transfusion 178
10.3.1 History 178
10.3.2 Access site 179
10.3.3 Method of transfusion 180
10.3.4 Amount to transfuse 181
10.3.5 The severely anaemic fetus 183
10.3.6 Adjunctive measures 183
10.3.7 Outcome 184
10.4 Red cells for transfusion 188
10.5 Experimental therapy 190
10.5.1 Immunoabsorption 190
10.5.2 Oral tolerance 191
10.5.3 Chemotherapeutic agents 191
10.5.4 Sensitization to paternal leukocyte antigens 192
10.6 Timing of delivery 193
10.7 Conclusion 193
10.8 References 193

11 Neonatal therapy for haemolytic disease of the newborn 203
Glynn Russell and Nic Goulden

11.1 Features of haemolytic disease in the neonate 203
11.1.1 Hydrops 203
11.1.2 Neonatal jaundice 204
11.1.3 Persistent anaemia 204
11.2 Laboratory diagnosis 204
11.3 General neonatal management 205
11.3.1 Communication 205
11.3.2 Resuscitation 205
11.4 Treatment of hydrops 206
11.5 Treatment of anaemia 206
11.5.1 Blood transfusion 206
11.5.2 Influence of fetal transfusions 209

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

11.5.3 Indications for transfusion 209
11.6 Treatment of neonatal jaundice 210
11.6.1 Phototherapy 210
11.6.2 Exchange blood transfusion 210
11.6.3 An integrated approach to treating neonatal jaundice 212
11.7 Experimental treatments 214
11.8 References 214

12 The diagnosis of alloimmune thrombocytopenia 219
Andrew G Hadley

12.1 Clinical aspects of diagnosis 219
12.2 Platelet antigen systems 220
12.2.1 Platelet antigens on glycoprotein IIb/IIIa 220
12.2.2 Platelet antigens on glycoprotein Ia/IIa 221
12.2.3 Platelet antigens on glycoprotein Ib/IX/V 221
12.3 Platelet antibody specificities involved in alloimmune thrombocytopenia 221
12.4 Laboratory diagnosis of alloimmune thrombocytopenia 224
12.4.1 Haematology 224
12.4.2 Assays for the detection of antiplatelet antibodies 225
12.4.3 DNA-based genotyping 227
12.4.4 Antibody characteristics and disease severity 228
12.5 Future perspectives 228
12.6 References 229

13 The immunological diagnosis of alloimmune neutropenia 235
Geoff Lucas

13.1 Introduction 235
13.2 Pathophysiology and clinical history 235
13.2.1 Immunogenicity of fetal neutrophils 235
13.2.2 Clinical manifestations and haematological findings 235
13.2.3 Differential diagnosis 236
13.3 The structure and function of antigens involved in alloimmune neutropenia 238
13.3.1 Nomenclature 238
13.3.2 Granulocyte-specific antigens 239
13.3.3 'Shared' antigens 243
13.3.4 Antibody specificities involved in alloimmune neutropenia 244
13.3.5 The function of granulocyte antigens 244
13.4 Laboratory diagnosis of alloimmune neutropenia 245
13.4.1 Assays for granulocyte antibodies 245

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Table of Contents
More information

13.4.2 Role of crossmatching and parental typing 247
13.4.3 Granulocyte antigen typing 247
13.5 References 248

14 Fetal and neonatal treatment of alloimmune thrombocytopenia 253
Michael F Murphy, Rachel Rayment, David Allen and David Roberts

14.1 Introduction 253
14.2 Neonatal management of alloimmune thrombocytopenia 254
14.2.1 Platelet transfusion 254
14.2.2 Intravenous immunoglobulin 256
14.2.3 Monitoring of the effectiveness of neonatal treatment 257
14.3 Antenatal management of alloimmune thrombocytopenia 257
14.3.1 Fetal blood sampling 258
14.3.2 Maternal treatment 259
14.3.3 Fetal platelet transfusion 263
14.3.4 Serial fetal platelet transfusions compared with maternal administration of high-dose intravenous immunoglobulin 267
14.3.5 Timing of the initial fetal blood sample 268
14.3.6 Strategy for the antenatal management of pregnancies at risk of very early intracranial haemorrhage 269
14.4 Preparation of platelet concentrates for transfusion in cases of alloimmune thrombocytopenia 270
14.4.1 Provision of HPA-typed platelets for neonates with alloimmune thrombocytopenia 270
14.4.2 Identification and recruitment of HPA-1a-negative and HPA-5b-negative donors 270
14.4.3 Preparation of platelet concentrates for fetal transfusions 271
14.5 Future directions 272
14.6 References 274

Index 279

© Cambridge University Press www.cambridge.org